The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)
To evaluate the efficacy of HAIC combine Lenvatinib and Durvalumab (HILL) in advanced HCC.
Hepatocellular Carcinoma
PROCEDURE: Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
PFS, progression-free survival, From date of randomization until the date of progression, assessed up to 36 months
ORR, objective response rate, From date of randomization until the date of death, assessed up to 36 months|DCR, disease control rate, From date of randomization until the date of death, assessed up to 36 months|OS, overall survival, From date of randomization until the date of death from any cause, assessed up to 36 months
To evaluate the efficacy of HAIC combine Lenvatinib and Durvalumab (HILL) in advanced HCC.